scholarly journals The Changing Natural History of HIV Disease: Before and After the Introduction of Generic Antiretroviral Therapy in Southern India

2005 ◽  
Vol 41 (10) ◽  
pp. 1525-1528 ◽  
Author(s):  
N. Kumarasamy ◽  
S. Solomon ◽  
S. K. Chaguturu ◽  
A. J. Cecelia ◽  
S. Vallabhaneni ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Natural History ◽  
Southern India ◽  
Hiv Disease ◽  
Before And After ◽  
History Of

scholarly journals Natural History of Human Immunodeficiency Virus Disease in Southern India

2003 ◽  
Vol 36 (1) ◽  
pp. 79-85 ◽  
Author(s):  
N. Kumarasamy ◽  
Suniti Solomon ◽  
Timothy P. Flanigan ◽  
R. Hemalatha ◽  
S. P. Thyagarajan ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Natural History ◽  
Virus Disease ◽  
Southern India ◽  
Human Immunodeficiency Virus Disease ◽  
Immunodeficiency Virus ◽  
History Of

Oral lesions among persons with HIV disease with and without highly active antiretroviral therapy in southern India

2007 ◽  
Vol 36 (3) ◽  
pp. 136-141 ◽  
Author(s):  
K. M. R. Umadevi ◽  
K. Ranganathan ◽  
S. Pavithra ◽  
R. Hemalatha ◽  
T. R. Saraswathi ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Southern India ◽  
Oral Lesions ◽  
Hiv Disease ◽  
Highly Active

scholarly journals Effect of highly active antiretroviral therapy (HAART) on the natural history of ocular manifestations in HIV-infected children

Eye ◽  
2006 ◽  
Vol 20 (5) ◽  
pp. 595-597 ◽  
Author(s):  
S Esposito ◽  
A Porta ◽  
J Bojanin ◽  
L Gualtieri ◽  
L Cesati ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Natural History ◽  
Highly Active Antiretroviral Therapy ◽  
Ocular Manifestations ◽  
Highly Active ◽  
History Of

Natural History of Patients with Low-Level HIV Viremia on Antiretroviral Therapy

2004 ◽  
Vol 18 (8) ◽  
pp. 436-442 ◽  
Author(s):  
Vincent Lo Re ◽  
Leanne Gasink ◽  
Jay R. Kostman ◽  
Debra Leonard ◽  
Robert Gross
Keyword(s):  
Antiretroviral Therapy ◽  
Natural History ◽  
Low Level ◽  
History Of

Causes of the decline in AIDS deaths, United States, 1995–2002: prevention, treatment or both?

2005 ◽  
Vol 16 (12) ◽  
pp. 777-781 ◽  
Author(s):  
David R Holtgrave
Keyword(s):  
Natural History ◽  
Highly Active Antiretroviral Therapy ◽  
Research Question ◽  
Current Treatment ◽  
Hiv Disease ◽  
Hiv Incidence ◽  
Highly Active ◽  
Scenario Analyses ◽  
The Usa ◽  
History Of

The decline in AIDS deaths in the USA between 1995 and 2002 has been attributed by Centers for Disease Control (CDC) to HIV treatments advances. The purpose of the present study is to assess whether this AIDS deaths decline was due entirely to treatment advances, to earlier prevention successes, or a combination of both. Secondarily, we quantitatively estimate the number of AIDS deaths averted (or delayed) by treatment advances over and above prevention effects. The study employed scenario analysis to address the research questions. To answer the primary research question, we examined whether three key predictions derived from the shape and peak of the HIV incidence curve in the USA (and the natural history of HIV disease in the era before highly active antiretroviral therapy [HAART]) about the shape and peak of the AIDS deaths curve were upheld (e.g., one prediction was that the peak of the AIDS deaths curve should occur 10–12 years after the peak of the HIV incidence curve). To the extent that these predictions are supported, there is evidence that earlier HIV prevention efforts impacted the number of AIDS deaths later in the epidemic. To answer the second research question, the observed annual AIDS deaths curve (1995–2002) was compared with three estimated AIDS deaths curves that may have occurred had HAART never became available. Three estimations were employed to reflect a range of assumptions about the lag between the flattening of HIV incidence in the USA and the flattening of AIDS deaths (i.e., 10, 11 or 12 years). For any one of the three-scenario analyses, the quantitative area between the 'observed' and 'estimated' AIDS deaths curves provide an estimate of the number of AIDS deaths averted by HIV/AIDS treatments. The three predictions from the HIV incidence curve (and the pre-HAART natural history of HIV disease) for determining the shape and peak of the AIDS deaths curve were supported thereby indicating the influence of past prevention efforts on recent AIDS deaths. However, the observed decline in AIDS deaths was more precipitous than predicted (indicating the influence of treatment advances). The scenario analyses indicated that between 33,480 and 41,784 AIDS deaths were averted (or delayed) between 1995 and 2002 as a function of treatment. That is, approximately, 206,037 AIDS deaths occurred between 1995 and 2002 (in the HAART era), but between 239,517 and 247,821 likely would have occurred without the advent of HAART. We conclude that both past prevention and current treatment services have lead to the AIDS deaths decline in the USA, and that HAART has averted between 33,480 and 41,784 AIDS deaths in the USA between 1995 and 2002 over and above the effects of early prevention efforts.

Abstract 15785: The Natural History of Doppler-Derived Left Ventricular Outflow Tract Gradients in Patients With Congenital Valvar Aortic Stenosis Before and After Balloon Valvuloplasty

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Joseph D Kuebler ◽  
Jill Shivapour ◽  
Kimberlee Gauvreau ◽  
Steven D Colan ◽  
Doff B McElhinney ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Natural History ◽  
Aortic Stenosis ◽  
Surgical Intervention ◽  
Left Ventricular ◽  
Mixed Effect ◽  
Congenital Aortic Stenosis ◽  
Rate Of Progression ◽  
Before And After ◽  
History Of

Introduction: Congenital aortic stenosis (AS) has been reported to manifest a slow rate of progression in mild disease with a greater likelihood of progression in patients with moderate-severe disease. The natural history of the Doppler estimated peak gradient (DEPG) in patients after balloon aortic valvuloplasty (BAV) has not previously been studied on a large scale. Methods: A retrospective review was performed of 360 patients from 1984-2012 with AS providing a total of 2051 echocardiograms before and after BAV. Patients were excluded if they had an intervention within the first 30 days of life. The relationships between the AS DEPG and several predictors (age at time of initial echocardiogram, valve morphology, and history of intervention) were explored using linear mixed effect models. The DEPG slope was then calculated in patients who had at least 2 echocardiograms before and after balloon dilation using linear regression modeling. Results: The rate of increase in the DEPG for all patients with AS was 5.6 mmHg per 10 years of age (p<0.001). The DEPG increased over time regardless of age at presentation with the greatest mean increase in patients presenting from 10-14.9 years (n=59; 11.9 mmHg per 10 years; p<0.001). Patients who went on to have a BAV or surgical intervention on the aortic valve had a significantly higher rate of AS progression than the overall patient cohort (n=59; 18.0 mmHg/10 years and n=36; 13.1 mmHg/10 years). Patients with a unicommissural (n=39) aortic valve had a significantly higher rate of progression compared to those with a bicommissural (n=270) aortic valve (8.1 mmHg/10 years and 4.5 mm Hg/10 years; p<0.001). The median rate of progression in the post-BAV group was significantly lower than the median pre-BAV rate of progression (n=34; pre-BAV 3.97 (1.69-8.7) mmHg/year; post-BAV 0.40 (-1.80-3.88) mmHg/year; p<0.01). Conclusions: The DEPG of native valve congenital aortic stenosis shows a slow, linear rate of progression prior to intervention. The rate of progression is significantly higher in patients with a unicommissural aortic valve as well as those patients that go on to have a BAV and/or surgical intervention. The rate of the DEPG progression is significantly lower after BAV.

Sign in / Sign up

Export Citation Format

Share Document